Agios Pharmaceuticals, Inc. (AGIO) Stock Price & How to Invest
Short answer
AGIO is Agios Pharmaceuticals, a US commercial-stage biotech built around mitapivat (branded PYRUKYND and AQVESME), a first-in-class pyruvate kinase activator for rare blood disorders. It is a clinical-catalyst story: real but small product revenue, deep losses, and a large cash pile funding sickle cell and thalassemia expansion.
AGIO stock price
As of 2026-07-08, Agios Pharmaceuticals, Inc. (AGIO) last closed at $42.76, up 9.4% over the past year. Over the past 52 weeks it has traded between $22.34 and $45.49.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Agios Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Agios Pharmaceuticals, Inc. (AGIO) do?
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia. The company is pursuing accelerated approval of mitapivat in sickle cell disease and, as of July 2026, the FDA granted Priority Review to that application. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).
The investment picture is a classic emerging-biotech profile. Product revenue is real but small (roughly $54 million in full-year 2025 and about $21 million in Q1 2026, more than doubling year over year), while research and commercial spending keep the company deeply unprofitable, with net losses of over a dollar-and-a-half per share per quarter. A cash and investments balance of around $1 billion as of March 2026 funds the pipeline through several near-term catalysts. The upside case rests on mitapivat expanding into far larger indications like sickle cell and thalassemia; the downside case is that trials disappoint (as the tebapivat lower-risk MDS program did in 2026) and the franchise stays niche while cash burns.
What's driving Agios Pharmaceuticals, Inc. (AGIO)?
1. Mitapivat franchise expansion
Agios is trying to grow mitapivat from a small PK-deficiency drug into a multi-disease franchise. AQVESME launched in US thalassemia in 2026, and the company is pursuing accelerated FDA approval in sickle cell disease, a much larger market. Each new indication meaningfully widens the potential patient base for a single molecule.
2. Sickle cell Priority Review
The FDA granted Priority Review to Agios' supplemental application for mitapivat in sickle cell disease (announced July 2026), which shortens the review timeline. A sickle cell approval would be the single largest addressable-market event for the company, and the stock reacted sharply to the news.
3. Strong balance sheet plus Servier royalty
Roughly $1 billion in cash and investments as of March 2026 funds operations through multiple pipeline readouts without immediate financing pressure. Agios also collects a royalty on US sales of Servier's Voranigo, a non-dilutive stream tied to a growing brain-cancer drug.
4. Next-generation PK activator pipeline
Beyond mitapivat, Agios is developing tebapivat, a next-generation PK activator, with a Phase 2 sickle cell readout expected in the second half of 2026. The company frames 2026 as a year of multiple value-driving inflection points across its hematology pipeline.
What are the risks to Agios Pharmaceuticals, Inc. (AGIO)?
Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. The business is heavily dependent on a single molecule, so a negative trial or regulatory setback is materially damaging, as shown when Agios halted tebapivat development in lower-risk myelodysplastic syndromes in 2026 after the trial missed its efficacy threshold. Sickle cell and thalassemia are competitive markets with gene therapies and other novel agents, and accelerated approval requires a confirmatory trial that could still fail. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is strong today, sustained losses without pipeline success would eventually pressure it.
How is Agios Pharmaceuticals, Inc. (AGIO) valued? (approximate, JUNE 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Agios Pharmaceuticals, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$66M
- FY2025 revenue: ~$54M
- Q1 2026 revenue: ~$20.7M (up ~138% YoY)
- Q1 2026 GAAP EPS: ~-$1.69
- Cash & investments: ~$1.0B (Mar 2026)
- Market cap: ~$2.1B
Agios trades at a large multiple of its small product revenue, reflecting a valuation driven by pipeline potential rather than current earnings. The company is unprofitable, with R&D (~$81M) and SG&A (~$48M) in Q1 2026 far exceeding revenue. The roughly $1 billion cash balance represents a large share of the market capitalization, which cushions financing risk but also signals that the market is paying primarily for future indications like sickle cell disease.
Who competes with Agios Pharmaceuticals, Inc. (AGIO)?
Sickle cell disease therapies
Companies with approved or developing sickle cell treatments, including gene therapies like Vertex and CRISPR Therapeutics' Casgevy, plus Pfizer (which acquired Oxbryta) and Novartis (Adakveo). These represent alternative treatment approaches in a market Agios is trying to enter with mitapivat.
PK activators and rare-hematology developers
Other developers of pyruvate kinase activators and rare blood-disorder drugs, notably Novo Nordisk (which is advancing etavopivat, a competing PK activator). This is the most direct competitive overlap with Agios' core mechanism.
Thalassemia and transfusion-dependent anemia treatments
Therapies for thalassemia and related anemias, including Bristol Myers Squibb's Reblozyl (luspatercept) and bluebird bio's gene therapy Zynteglo, which compete for the same patient populations AQVESME targets.
How to invest in Agios Pharmaceuticals, Inc. (AGIO)
There are three common ways to get AGIO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so AGIO sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where AGIO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Agios Pharmaceuticals, Inc. (AGIO)
AGIO is a rare-disease biotech whose value hinges on turning one approved PK activator into a multi-indication franchise, with a well-funded balance sheet buying time but ongoing losses and binary trial and FDA outcomes defining the risk.
More on Agios Pharmaceuticals, Inc. (AGIO)
Whether AGIO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AGIO a buy?, and where the stock could go from here in the AGIO stock forecast.
For income investors, whether AGIO pays a dividend and how the payout looks is covered in does AGIO pay a dividend?
Build a basket around AGIO with Walnut
Use Agios Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Agios Pharmaceuticals do?
+
Agios develops medicines for rare hematologic (blood) diseases. Its main product is mitapivat, a pyruvate kinase activator sold as PYRUKYND for PK deficiency and AQVESME for thalassemia, and it is pursuing approval in sickle cell disease.
Is AGIO profitable?
+
No. As of Q1 2026 Agios reported a GAAP loss of about $1.69 per share. Research and commercial spending far exceed its roughly $21 million of quarterly product revenue, so the company remains deeply unprofitable.
How much revenue does Agios generate?
+
Agios reported about $54 million in full-year 2025 product revenue and roughly $20.7 million in Q1 2026, up about 138% year over year. Trailing-twelve-month revenue is in the neighborhood of $66 million as of mid-2026.
What is mitapivat (PYRUKYND and AQVESME)?
+
Mitapivat is an oral pyruvate kinase activator. It is approved as PYRUKYND for pyruvate kinase deficiency and as AQVESME for thalassemia, and Agios is seeking accelerated approval for its use in sickle cell disease.
What happened with tebapivat?
+
In 2026 Agios discontinued tebapivat development in lower-risk myelodysplastic syndromes after a Phase 2b trial failed to meet its efficacy threshold for durable transfusion independence. Tebapivat is still being studied in sickle cell disease, with data expected in the second half of 2026.
How much cash does Agios have?
+
Agios reported roughly $1.0 billion in cash, cash equivalents, and marketable securities as of March 31, 2026. That balance funds its pipeline through several near-term clinical and regulatory catalysts.
What is the Priority Review news about?
+
In July 2026 the FDA granted Priority Review to Agios' supplemental application for mitapivat in sickle cell disease, shortening the review timeline. The stock rose sharply on the news because sickle cell is a much larger market than PK deficiency.
What are the main risks with AGIO?
+
Key risks include heavy ongoing losses, dependence on a single molecule, competitive markets including gene therapies, and binary trial and regulatory outcomes. Walnut is not an investment adviser, and this page is descriptive information, not a recommendation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Agios Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.